［1］BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］PIGNON JP,TRIBODET H,SCAGLIOTTI GV,et al.Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Group［J］.J Clin Oncol,2008,26(21):3552-3559.
［3］FAN DM,WANG JX,LI JY,et al.CACA guidelines for holistic integrative management of cancer.Lung cancer［M］.Tianjin:Tianjin Science & Technology Publishing House,2022:549-628.
［4］NSCLC Meta-analysis Collaborative Group.Preoperative chemotherapy for non-small-cell lung cancer:a systematic review and meta-analysis of individual participant data［J］.Lancet,2014,383:1561-1571.
［5］COLEMAN CN,LAWRENCE TS,KIRSCH DG.Enhancing the efficacy of radiation therapy:premises,promises,and practicality［J］.J Clin Oncol,2014,32:2832-2835.
［6］TIMMERMAN RD,HERMAN J,CHO LC.Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice［J］.J Clin Oncol,2014,32:2847-2854.
［7］SHAMPAIN KL,HACKETT CE,TOWFIGHI S,et al.SBRT for HCC:Overview of technique and treatment response assessment［J］.Abdom Radiol,2021,46:3615-3624.
［8］MELOSKY B,KAMBARTEL K,HANTSCHEL M,et al.Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer:A meta-analysis［J］.Mol Diagn Ther,2022,26:7-18.
［9］BOUMAHDI S,DE SAUVAGE FJ.The great escape:tumour cell plasticity in resistance to targeted therapy［J］.Nat Rev Drug Discov,2020,19:39-56.
［10］O' DONNELL JS,HOEFSMIT EP,SMYTH MJ,et al.The promise of neoadjuvant immunotherapy and surgery for cancer treatment［J］.Clin Cancer Res,2019,25:5743-5751.
［11］GETTINGER SN,HORN L,GANDHI L,et al.Overall survival and long-term safety of nivolumab(anti-programmed death 1 antibody,BMS-936558,ONO-4538) in patients with previously treated advanced non-small cell lung cancer［J］.J Clin Oncol,2015,33:2004-2012.
［12］RITTMEYER A,BARLESI F,WATERKAMP D,et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK):a phase 3,open-label,multicentre randomised controlled trial［J］.Lancet,2017,389:255-265.
［13］LIANG WH,CAI KC,CHEN C,et al.Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer［J］.Transl Lung Cancer Res,2020,9:2696-2715.
［14］KEPP O,GALLUZZI L,MARTINS I,et al.Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy［J］.Cancer Metastasis Rev,2011,30:61-69.
［15］FORDE PM,CHAFT JE,SMITH KN,et al.Neoadjuvant PD-1 blockade in resectable lung cancer［J］.N Engl J Med,2018,378:1976-1986.
［16］PROVENCIO M,NADAL E,INSA A,et al.Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer(NADIM):an open-label,multicentre,single-arm,phase 2 trial［J］.Lancet Oncol,2020,21:1413-1422.
［17］SHEN DJ,WANG JF,WU J,et al.Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage Ⅱb-Ⅲbresectable lung squamous cell carcinoma［J］.J Thorac Dis,2021,13:1760-1768.
［18］LIANG HR,YANG C,GONZALEZ-RIVAS D,et al.Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer［J］.Transl Lung Cancer Res,2021,10:143-155.
［19］SHU CA,GAINOR JF,AWAD MM,et al.Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer:an open-label,multicentre,single-arm,phase 2 trial［J］.Lancet Oncol,2020,21:786-795.
［20］LI X,LI QY,YANG FJ,et al.Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non-small cell lung cancer［J］.J Thorac Cardiovasc Surg,2023,166:1234-1244.e13.
［21］FORDE PM,SPICER J,LU S,et al.Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer［J］.N Engl J Med,2022,386:1973-1985.
［22］ROTHSCHILD SI,ZIPPELIUS A,EBOULET EI,et al.SAKK 16/14:Durvalumab in addition to neoadjuvant chemotherapy in patients with stage ⅢA(N2) non-small-cell lung cancer-a multicenter single-arm phase Ⅱ trial［J］.J Clin Oncol,2021,39:2872-2880.
［23］ZHOU Q,CHEN M,JIANG O,et al.Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced,unresectable,stage Ⅲ non-small-cell lung cancer in China(GEMSTONE-301):interim results of a randomised,double-blind,multicentre,phase 3 trial［J］.Lancet Oncol,2022,23:209-219.
［24］HEYMACH JV,MITSUDOMI T,HARPOLE D,et al.Design and rationale for a phase Ⅲ,double-blind,placebo-controlled study of neoadjuvant durvalumab+chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages Ⅱ and Ⅲ non-small-cell lung cancer:The AEGEAN trial［J］.Clin Lung Cancer,2022,23:e247-e251.
［25］ZHANG BH,XIAO HF,PU XX,et al.A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer［J］.Cancer Med,2023,12:274-286.
［26］CHEN TX,NING JW,SHEN JF,et al.Sleeve lobectomy after neoadjuvant chemoimmunotherapy versus chemotherapy for squamous cell lung cancer:A multicenter,retrospective study［J］.JTO Clin Res Rep,2023,4:100472.
［27］THOMAS PA,BERBIS J,BASTE JM,et al.Pneumonectomy for lung cancer:contemporary national early morbidity and mortality outcomes［J］.J Thorac Cardiovasc Surg,2015,149:73-82.
［28］MUN M,NAKAO M,MATSUURA Y,et al.Video-assisted thoracoscopic surgery lobectomy for non-small cell lung cancer［J］.Gen Thorac Cardiovasc Surg,2018,66:626-631.
［29］VENUTA F,ANILE M,DISO D,et al.Operative complications and early mortality after induction therapy for lung cancer［J］.Eur J Cardiothorac Surg,2007,31:714-717.
［30］CHEN YL,ZHANG LM,YAN B,et al.Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer［J］.Transl Lung Cancer Res,2020,9:761-767.
［31］DENG HS,LIU J,CAI XY,et al.Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage Ⅲb non-small cell lung cancer［J］.Ann Surg,2022,275:e600-e602.
［32］BEATTIE R,FURRER K,DOLAN DP,et al.Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors:safety and clinical outcomes［J］.Eur J Cardiothorac Surg,2021,60:1297-1305.
［33］AIDE N,HICKS RJ,LE TOURNEAU C,et al.FDG PET/CT for assessing tumour response to immunotherapy:Report on the EANM symposium on immune modulation and recent review of the literature［J］.Eur J Nucl Med Mol Imaging,2019,46:238-250.
［34］CASCONE T,WEISSFERDT A,GODOY MCB,et al.Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer［J］.Nat Commun,2021,12:5045.
［35］ROMERO ROMAN A,CAMPO-CANAVERAL DE LA CRUZ JL,MACIA I,et al.Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage ⅢA non-small-cell lung cancer［J］.Eur J Cardiothorac Surg,2021,60:81-88.
［36］HELLMANN MD,CHAFT JE,WILLIAM WN,et al.Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers:proposal for the use of major pathological response as a surrogate endpoint［J］.Lancet Oncol,2014,15:e42-50.
［37］FORMENTI SC,DEMARIA S.Systemic effects of local radiotherapy［J］.Lancet Oncol,2009,10:718-726.
［38］WEICHSELBAUM RR,LIANG H,DENG LF,et al.Radiotherapy and immunotherapy:a beneficial liaison［J］.Nat Rev Clin Oncol,2017,14:365-379.
［39］DOVEDI SJ,ADLARD AL,LIPOWSKA-BHALLA G,et al.Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade［J］.Cancer Res,2014,74:5458-5468.
［40］DENG LF,LIANG H,BURNETTE B,et al.Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice［J］.J Clin Invest,2014,124:687-695.
［41］ALTORKI NK,MCGRAW TE,BORCZUK AC,et al.Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer:a single-centre,randomised phase 2 trial［J］.Lancet Oncol,2021,22:824-835.
［42］HUANG K,DAHELE M,SENAN S,et al.Radiographic changes after lung stereotactic ablative radiotherapy(SABR)-can we distinguish fibrosis from recurrence? A systematic review of the literature［J］.Pract Radiat Oncol,2013,3:S11-12.
［43］LEHRER EJ,SINGH RAJ,WANG M,et al.Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer:A systematic review and Meta-analysis［J］.JAMA Oncol,2021,7:92-106.
［44］SCHOENFELD JD,GIOBBIE-HURDER A,RANASINGHE S,et al.Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy:an open-label,multicentre,randomised,phase 2 trial［J］.Lancet Oncol,2022,23:279-291.
［45］KROEZE SGC,PAVIC M,STELLAMANS K,et al.Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy:systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium［J］.Lancet Oncol,2023,24:e121-e132.
［46］JIAO XD,HE X,QIN BD,et al.The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma,an analysis based on cBioPortal data base［J］.J Thorac Dis,2019,11:4507-4515.
［47］MAZIERES J,DRILON A,LUSQUE A,et al.Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations:results from the IMMUNOTARGET registry［J］.Ann Oncol,2019,30:1321-1328.
［48］UPRETY D,MANDREKAR SJ,WIGLE D,et al.Neoadjuvant immunotherapy for NSCLC:current concepts and future approaches［J］.J Thorac Oncol,2020,15:1281-1297.
［49］ZHONG WZ,CHEN KN,CHEN C,et al.Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage ⅢA-N2 EGFR-mutant non-small-cell lung cancer(EMERGING-CTONG 1103):A randomized phase Ⅱ study［J］.J Clin Oncol,2019,37:2235-2245.
［50］ZHANG C,CHEN HF,YAN S,et al.Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC:A multicenter pooled analysis［J］.NPJ Precis Oncol,2022,6:66.